Can Gene Editing Techniques Like CRISPR-Cas9 Be Used to Replace Mutated Genes in CF?
The FDA approval of the CFTR modulator, Kayldeco, in 2012 changed the paradigm of CF healthcare by providing a therapy to address the underlying cause of the disease. The previous paradigm in CF care was limited to only treat the symptoms of CF, such as inflammation, bacterial infection and…